{"id":"NCT05393895","sponsor":"Orasis Pharmaceuticals Ltd.","briefTitle":"An Evaluation of the Safety of CSF-1 in Presbyopic Subjects","officialTitle":"A Multi-Center, Double-Masked, Vehicle-Controlled, Evaluation of the Safety of CSF-1 in Presbyopic Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-04-22","primaryCompletion":"2022-12-01","completion":"2022-12-01","firstPosted":"2022-05-26","resultsPosted":"2025-06-11","lastUpdate":"2025-06-11"},"enrollment":178,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Presbyopia"],"interventions":[{"type":"DRUG","name":"CSF-1","otherNames":["Qlosi"]},{"type":"DRUG","name":"Vehicle","otherNames":[]}],"arms":[{"label":"CSF-1","type":"EXPERIMENTAL"},{"label":"Vehicle","type":"PLACEBO_COMPARATOR"}],"summary":"This is a multi-center, double-masked, vehicle-controlled study. The purpose of the study is to evaluate the safety of CSF-1 compared with vehicle in presbyopic subjects. Subjects will be treated for at least 6 weeks.","primaryOutcome":{"measure":"Number of Participants With Treatment Emergent Adverse Events.","timeFrame":"Adverse events were collected over a period of at least 6 weeks and up to 21 weeks for the last participants exiting the study.","effectByArm":[{"arm":"CSF-1","deltaMin":43,"sd":null},{"arm":"Vehicle","deltaMin":16,"sd":null}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":12,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":118},"commonTop":["Instillation site pain","Vision blurred","Conjuctival papillae","Conjunctival hyperaemia","COVID-19"]}}